JP2020530007A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530007A5
JP2020530007A5 JP2020506300A JP2020506300A JP2020530007A5 JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5 JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5
Authority
JP
Japan
Prior art keywords
psma
alkyl
drug composition
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027106 external-priority patent/WO2018191376A2/en
Publication of JP2020530007A publication Critical patent/JP2020530007A/ja
Publication of JP2020530007A5 publication Critical patent/JP2020530007A5/ja
Priority to JP2023061616A priority Critical patent/JP2023093545A/ja
Priority to JP2024199226A priority patent/JP2025028897A/ja
Pending legal-status Critical Current

Links

JP2020506300A 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ Pending JP2020530007A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023061616A JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
US62/484,219 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061616A Division JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Publications (2)

Publication Number Publication Date
JP2020530007A JP2020530007A (ja) 2020-10-15
JP2020530007A5 true JP2020530007A5 (https=) 2021-05-20

Family

ID=63792979

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506300A Pending JP2020530007A (ja) 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Country Status (10)

Country Link
US (1) US12508271B2 (https=)
EP (1) EP3609544B1 (https=)
JP (3) JP2020530007A (https=)
KR (1) KR102686172B1 (https=)
CN (1) CN111801121B (https=)
AU (1) AU2018250609B2 (https=)
ES (1) ES3021195T3 (https=)
IL (1) IL269969B2 (https=)
SG (1) SG11201909513QA (https=)
WO (1) WO2018191376A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
EP3853213A4 (en) * 2018-09-21 2022-07-06 Endocyte, Inc. Shielding agents and their use
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
TWI905175B (zh) * 2020-04-29 2025-11-21 瑞士商諾華公司 放射性標記psma結合配位體的方法及其套組
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
JP2023547998A (ja) * 2020-10-01 2023-11-15 コーネル ユニバーシティー 低分子リガンドの取り込み、内在化、及び/または保持を増加させるための方法及び組成物
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
CA2961575C (en) * 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
PL3177632T3 (pl) * 2014-08-06 2022-06-13 The Johns Hopkins University Proleki inhibitora antygenu błony swoistego dla stercza (PSMA)
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護

Similar Documents

Publication Publication Date Title
JP2020530007A5 (https=)
CN1318388C (zh) 在光化学疗法中作为光敏剂的5-氨基乙酰丙酸的酯类
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
AU2018366219B2 (en) Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
JP2019529518A5 (https=)
JP2010501584A5 (https=)
AU2017302539B2 (en) Targeted radiotherapy chelates for In Situ Immune Modulated Cancer Vaccination
JP2008530240A (ja) 増殖性疾患の治療のための化合物
JP2007509928A5 (https=)
JP5149177B2 (ja) 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
JP2009544582A5 (https=)
JP2024544870A5 (https=)
JP2005538051A5 (https=)
JP2019011381A5 (https=)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2016515615A5 (https=)
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
US20190184021A1 (en) Porphyrin Compounds and Compositions Useful for Treating Cancer
Patterson et al. Combretastatin A-4 phosphate
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
JP2020532538A5 (https=)
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
AU2020341213B2 (en) Pharmaceutical composition comprising HDAC inhibitor and anti-PD1 antibody or anti PD-L1 antibody
RU2019104928A (ru) Производное индола, используемое в качестве ингибитора CRTH2
JP5322651B2 (ja) シンチグラフィー法